Obtained a PhD in Clinical Surgery from Beijing Medical University in 1995, with extensive clinical experience in the treatment of hepatocellular carcinoma.
From 2008 to 2017, he successively joined multinational pharmaceutical companies such as Roche Pharmaceuticals in the United States, Roche Pharmaceuticals in Switzerland, and Express Scripts as Vice Director, Director, and Senior Director of Clinical Research. As a core member of the project, he participated in the clinical research and development of world-class drugs AVASTIN, VEMURAFENIB, OCRELIZUMAB, and TAGRESS, and successfully promoted the successful development of the drugs and later obtained FDA approval for market.
In 2017, as a co-founder, Teclison Limited was founded in the United States, serving as the CMO of the company. The company developed a new global small molecule drug for the treatment of hepatocellular carcinoma, which has been granted orphan drug status by the FDA. The company successfully held IND meetings with the FDA, EMA, and NMPA, and completed phase I and II clinical trials in the United States and China. Currently, it is undergoing successful phase III registration clinical trials worldwide.
Founded in 2024, Hangzhou Kunyu Biopharmaceutical focuses on the research and development of nanobody nuclear drug RDC and coupling drug NDC.
I graduated from Dalian Medical University with a bachelor's degree in 1988.